Technology-Enabled Skin Cancer Screening for Stem Cell Transplant Survivors

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: City of Hope Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to improve early detection of skin cancer in individuals who have undergone stem cell transplants. Participants will receive educational materials and regular text message reminders to help them identify skin changes early. Some participants' doctors will also receive resources to support skin checks during visits, and some will receive a tool (dermatoscope) to better examine skin changes. This trial is for stem cell transplant survivors who had the procedure at City of Hope between two and five years ago and who have a mobile phone for receiving texts. As an unphased trial, it offers a unique opportunity to contribute to research that could enhance post-transplant care and early cancer detection.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this intervention is safe for stem cell transplant survivors?

Research has shown that educational programs for both patients and doctors are generally safe and well-received. Studies indicate that patient support programs can improve cancer care by helping patients understand their treatment and feel supported, without causing harm. For doctors, educational programs enhance their ability to detect skin cancer early, leading to better patient outcomes. The safety of these educational efforts is well-documented, as they focus on increasing knowledge and awareness.

Additionally, using a dermatoscope, a tool for closely examining skin spots, is common in skin care and is considered safe and non-invasive. Although specific safety data for these programs is not provided, the methods used are widely accepted in medical practice, suggesting they are well-tolerated by participants.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores innovative ways to enhance skin cancer screening for stem cell transplant survivors. Unlike standard screenings, which typically rely on patient or physician-initiated consultations, this approach integrates regular educational interventions and digital communication to keep participants informed and vigilant. One unique feature is the use of a dermatoscope by trained physicians, enhancing diagnostic precision through high-quality imaging. The trial also empowers patients with knowledge and regular reminders, potentially leading to earlier detection and improved outcomes. Overall, this method could streamline the screening process and make it more proactive and accessible for patients.

What evidence suggests that this trial's interventions could be effective for early detection of skin cancer in stem cell transplant survivors?

Research has shown that educational programs can help individuals who have undergone stem cell transplants detect skin cancer early. In this trial, participants in Group I will receive educational materials and regular text messages to support early detection. Group II participants will receive the same educational materials and text messages, with their physicians encouraged to perform skin examinations. Group III participants will receive all these interventions, and their physicians will also receive a dermatoscope and training to enhance early detection. One study found that patients who learned about preventing skin cancer retained this information well. Another study demonstrated that programs assisting patients in navigating the healthcare system increased their participation in cancer screenings. When doctors are involved, these efforts often prove more effective, as they can guide and encourage patients to check their skin regularly. Tools like a dermatoscope, which enhances the visibility of skin details, can also improve early detection. Overall, these combined strategies can lead to better outcomes by identifying skin cancer sooner.16789

Who Is on the Research Team?

SH

Saro H Armenian

Principal Investigator

City of Hope Comprehensive Cancer Center

Are You a Good Fit for This Trial?

This trial is for stem cell transplant survivors who are 2-5 years post-transplant, can read and write in English or Spanish, have seen a primary care provider recently or plan to within a year, and can receive text messages. Those with active cancer or acute illness that limits participation cannot join.

Inclusion Criteria

Have a mobile phone with the ability to receive text messages
I had a stem cell transplant at City of Hope.
Have seen a primary care provider (PCP) in the previous 12 m (expected > 95% of all eligible) or planning to do so in next 12 m
See 3 more

Exclusion Criteria

I do not have an active blood cancer or severe illness that would prevent me from participating in the study.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive a study packet on skin cancer and text messages every 3 weeks for 9 months. Physicians may receive additional educational materials and tools.

9 months

Follow-up

Participants are monitored for changes in skin cancer screening practices and health promotion activities.

3 months

What Are the Treatments Tested in This Trial?

Interventions

  • Computer-Assisted Intervention
  • Dermatoscope
  • Educational Intervention
  • Educational Intervention (Physician)
  • Questionnaire Administration
  • Text Message
Trial Overview The TEACH Study tests a 12-month program aimed at early skin cancer detection in stem cell transplant survivors. It includes education for both patients and doctors, questionnaires, computer tools, dermatoscopes for skin examination, and follow-up via text messaging.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Group I: Group III (PAE, physician, dermatoscope)Experimental Treatment6 Interventions
Group II: Group II (PAE, physician)Experimental Treatment4 Interventions
Group III: Group I (PAE)Experimental Treatment3 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

City of Hope Medical Center

Lead Sponsor

Trials
614
Recruited
1,924,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Citations

Technology-enabled activation of skin cancer screening for ...Despite the unique risk factors and extremely high rates of skin cancer among HCT survivors, less than 20% of survivors report having performed ...
Technology-Enabled Activation of Skin Cancer Screening ...This study focuses on one complication that stem cell transplant survivors are at high risk of developing - skin cancer. An early diagnosis of skin cancer ...
Skin cancer screening after solid organ transplantationThe primary outcome was the proportion of transplant clinic personnel who responded that their patients of white race underwent skin cancer screening at least ...
Screening Improves Skin Cancer Detection After TransplantAt baseline, SOT recipients had a 7.8-fold higher risk of developing skin cancer compared with nonrecipients (HR, 7.78; 95% CI, 5.97-10.10).
Delayed Time to First Skin Cancer Among Hematopoietic ...Conclusions HSCT recipients with cutaneous cGVHD demonstrate delayed onset of first skin cancer but accelerated development of subsequent ...
After a Transplant: New DangersThe risk of developing squamous cell carcinoma is about 100 times higher after a transplant.
Comparison of Patient and Provider Practices between ...Patients receiving immunosuppressive therapy following transplantation are at risk for skin cancer owing to dampened tumor surveillance.
Skin Cancer Surveillance Program for Solid Organ Transplant ...Skin cancer is a frequent long-term complication after solid organ transplantation, with approximately 8% of all transplant recipients ...
Comparison of Patient and Provider Practices between ...Although recipients are aware of skin cancer risk, many do not practice sun safety. Most transplant recipients have never had a full body skin exam.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security